Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 12, 2013 (13 years ago)

Propofol Injectible Emulsion

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Particulate Matter: Glass defect located on the interior neck of the vial identified glass surface abrasions and visible embedded particulate matter which could result in the potential for small glass flakes or embedded metal particulate to become dislodged into the solution.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Propofol Injectible Emulsion, 1%, 200 mg/20 mL (10 mg/mL), 20 mL Single patient infusion vial, packaged in 5 Units x 20 mL per carton, Rx only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-4699-30.

Affected NDC 0409-4699-30

Compare with the code on your package — it is the most precise check available.

Drug: Propofol

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Propofol
NDC 00409-4699
10 mg/mL Injection, Emulsion
Intravenous
Hospira, Inc. Rx
Recalling firm
Hospira Inc.
NDC code
0409-4699-30
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1033-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Propofol recalls

See all
Class II · Moderate risk

Diprivan (Propofol)

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 63323-269-29 D-1116-2022
Class II · Moderate risk

Diprivan (Propofol)

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 63323-269-10 D-1115-2022

Other recalls by Hospira Inc.

All 2013 recalls
Class II · Moderate risk

DOBUTamine Injection

Discoloration: Firm received complaints of product discoloration and particulates.

Terminated Failed specification Hospira Inc. NDC 0409-2025-20 D-1500-2016